CLOs on the Move

Context Therapeutics

www.contexttherapeutics.com

 
Context Therapeutics Inc. (Nasdaq: CNTX) is a women`s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The Company`s robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a novel small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women`s cancers.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Alex Levit
 Chief Legal Officer Profile

Similar Companies

Forest Labs

Forest Labs is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Prospect Biosystems

Prospect Biosystems is a Newark, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sirtris Pharmaceuticals

Sirtris Pharmaceuticals is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Memphis Chemical and Janitorial Supply De(3B's)

Memphis Chemical and Janitorial Supply De(3B's LLC) is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

POZEN

POZEN Inc. is a specialty pharmaceutical company that to date has historically focused on developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.